Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251368 · ClinicalTrials.gov registry record · Phase 1
Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT00251368 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 52 participants.
The verdict
NCT00251368, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the side effects of 9-Aminocamptothecin (9-AC) and to determine the best dose which should be used to treat leukemia.
Interventions
- DRUG 9-Aminocamptothecin (9-AC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 1995-01 |
| Est. Completion | 2007-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00251368
The ClinicalTrials.gov registry entry for NCT00251368 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 9-Aminocamptothecin (9-AC) is the first listed.
NCT00251368 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00251368 about?
NCT00251368 is a clinical study titled "Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia". The purpose of this study is to evaluate the side effects of 9-Aminocamptothecin (9-AC) and to determine the best dose which should be used to treat leukemia.
What is the current status of trial NCT00251368?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 1995-01. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00251368?
The interventions under investigation include: 9-Aminocamptothecin (9-AC) (DRUG).
Who is sponsoring clinical trial NCT00251368?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.